Americans for Safe Access Releases CBD Guide

Americans for Safe Access, an organization that brings together scientists, medical professionals, patients and other categories of people who are interested in seeing cannabis being used in a safe and legal way, recently released a CBD guide to bring some clarity to this compound whose popularity is exploding in the U.S. and around the world.

The guide was based on the work researchers did to comb through medical committee reports, 100 journal articles and lots of websites.

The introduction of the guide points out that there are a lot of myths and misconceptions surrounding cannabidiol (CBD). The guide intends to provide the facts and address the myths, Ethan Russo, the International Cannabis and Cannabinoid Institute’s director for research and development, wrote in the foreword to the CBD guide.

The guide extensively addresses matters of CBD dosing and packaging, among other aspects of interest.

In the guide, Americans for Safe Access writes that the patient’s medical history and the potency of the CBD product need to be considered when determining the “optimal” dosage of the product.

The guide also cautions that anyone taking a concentrated or purified form of CBD has to be very cautious when taking the product because taking too little or too much could compromise the effectiveness of CBD. The guide points out research findings that show that the therapeutic effects of CBD reduce when a certain sweet spot is exceeded or when that required dosage isn’t consumed.

Patients taking a full-spectrum CBD product are advised to start at a higher dosage than those taking a pure or concentrated form of CBD. However, the smallest dose delivering the desired effects should be identified so that the risk of side effects is avoided and costs are kept minimal.

One section that all interested people, especially patients, will find very useful is advice on how to keep a journal of one’s CBD usage. Americans for Safe Access recommends that patents track several metrics, such as the cultivar, the amounts taken, the side effects observed, the benefits noted, the mood or feelings after consuming the product, the mode of administration and so many other metrics.

On matters of product packaging, the CBD guide acknowledges that the lack of FDA oversight has created a loophole through which some CBD products may be packaged in a way that doesn’t accurately depict the ingredients in the product. The guide points out some research done showing that labelling issues exist in a significant proportion of the products on the market.

Patients are therefore advised to buy their products from a licensed medical marijuana dispensary if they can, or to do their own research about a product before purchasing it. For example, patients are advised to find out whether any third-party test results are available for the CBD products they wish to purchase.

All in all, the guide provides valuable information that experts believe will be a helpful addition to the information shared by CBD industry players like TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) and VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF).

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722